UK's NICE recommends against coverage for AstraZeneca and Daiichi's breast cancer drug Enhertu over cost-effectiveness

The UK’s National Institute for Health and Care Excellence (NICE) said Tuesday that it won’t recommend coverage of AstraZeneca and Daiichi Sankyo’s cancer drug Enhertu for treating advanced HER2-low breast cancer in adults.

NICE said that while NHS England has been negotiating with the company over the price of the drug since December, they weren’t able to reach an agreement. It’s not a huge surprise — NICE’s draft guidance in September said it didn’t recommend Enhertu because of doubts around its cost-effectiveness.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。